The effect of local and systemic delivery of the angiostatin gene on human melanoma growth was studied in nude mice. Liposomecoated plasmids carrying the cDNA coding for murine and human angiostatin ( CMVang and BSHang ) were injected weekly, locally or systemically, in mice transplanted with melanoma cells. The treatment reduced melanoma growth by 50% to 90% compared to that occurring in control animals treated with liposome -coated plasmid carrying the lacZ gene or in untreated controls. The growth of both locally injected and controlateral uninjected tumors in mice bearing two melanoma grafts was significantly suppressed after intratumoral treatment. Tumor growth inhibition was also observed in mice treated by intraperitoneal delivery, suggesting that angiostatin gene therapy acts through a systemic effect. Both melanoma growth suppression and delay in the onset of tumor growth were observed in treated mice. PCR performed on tumors and normal tissues showed that the lipofected DNA was present in tissues from treated mice, and angiostatin expression was demonstrated by RT -PCR. Histopathological analysis of melanoma nodules revealed an increase in apoptotic cells and a reduction in vessel density in tumors from treated mice. Our results suggest that systemic, liposome -mediated administration of genes coding for antiangiogenic factors represents a promising strategy for melanoma treatment in humans. Cancer Gene Therapy ( 2001 ) 8, 491 ± 496
A ngiogenesis has been correlated with melanoma progression. Transition from the radial to the vertical growth phase, which is considered the critical switch in melanoma progression, depends on the formation of new capillary vessels. 1 ± 5 In addition, the density of microvessels in primary melanomas has been found to gradually increase along with the simultaneous presence of local and distant metastases, thus indicating that angiogenesis has a role in the process of melanoma metastasis. 6 ± 8 Gene delivery of angiostatic factors represents an innovative approach to cancer treatment, which could also act in concert with other therapeutic strategies of tumor cells targeting. 9 Several antiangiogenic proteins have been identified that suppress the growth of cancer metastases while being released into the blood flow from a primary tumor site. Among these, angiostatin and endostatin, both proteolytic fragments of plasminogen and collagen XVIII, respectively, are probably the most potent and promising antitumoral agents, acting through antiangiogenic mechanisms, identified so far. They show selectivity for tumorderived endothelial cells, absence of apparent toxicity, and lack of resistance induction after prolonged administration. 10 Direct in vivo delivery of the angiostatin gene could represent an alternative approach to purified protein administration and allows reaching continuous high levels of angiostatin, which are needed to obtain optimal clinical benefits. Retroviral and adenoviral vectors that transduce the angiostatin cDNA were shown to inhibit angiogenesis in vivo and human breast carcinoma growth in athymic mice when given intratumorally. 11, 12 In addition, nonviral delivery of angiostatin gene by cationic liposomes inhibited tumor growth when given locally in immunocompromised mice bearing breast tumor xenografts or in transgenic mice developing mammary tumors because of activated neu transgene activity targeted to their mammary glands. 13, 14 We and others have recently reported that it is also possible to achieve similar effects by the systemic delivery of liposome complexed to therapeutic DNA constructs. 15, 16 As a further step in the preclinical evaluation of angiostatin as a potential clinically useful agent against human melanoma, the present study was undertaken to evaluate the antitumoral efficacy of such treatments against human melanoma. We report here that systemic liposome-mediated angiostatin gene administration is effective against human melanoma xenografted in nude mice.
METHODS

DNA constructs
The generation of MMTVang and of BSHang constructs, carrying murine or human angiostatin, respectively, has been previously described. 14, 16 The CMVang construct was prepared by substituting the MMTV promoter excised as SalI/HindIII fragment from the MMTVang construct with a SalI/HindIII CMV promoter. The PGKlacZ construct was produced by substituting the neo R gene in PGKneo vector with the lacZ gene from PCH110 (Stratagene, Amsterdam, the Netherlands ). DNA constructs were purified with the Endofree plasmid maxi Kit ( Qiagen, Germany ) and added to the Dosper liposomal transfection agent (Roche Diagnostics, Monza, Italy ) according to manufacturer instructions, as described previously.
14 For local treatments, 50 L of Dosper / DNA mixture containing 2 g of DNA were injected intratumorally, whereas for systemic treatments, 100 L of Dosper / DNA mixture containing 6 g of DNA were injected intraperitoneally; these doses were selected on the basis of our previous studies.
14,16
Analysis of DNA integration and expression DNA and RNA were extracted according to standard procedures from liver, kidney, lungs, and tumors from all the treated and untreated mice. DNAs and retrotranscribed P < .05 for ( A ) ± ( E ) comparison of treated vs. control growth curves by Student's t test; for data shown in ( F ), P < .05 for data points at 28, 35, and 42 days. Me501 was injected at the dose of 2Â10 6 cells in the experiments shown in ( A ), ( C ), and ( D ), and at the dose of 3Â10 6 in the experiments shown in ( E ) and ( F ); 10 6 1402P melanoma cells were used in the experiment shown in ( B ).
RNAs were subjected to PCR analysis with the following primers: Ang338F, 5
H GGA ACC ATG TCC AGG ACA AAG and Ang1097R, 5 H GGA ACT GAG GAA TCT GAC TGG, which amplify a fragment of 759 bp (for the detection of CMVang and MMTVang constructs ); BSHangF, 5 H GAA CTA CAG AGG GAC GAT GTC CTC and BSHangR, 5
H CAG AAG ATG GTG GAG GTG TTG, which amplify a fragment of 481 bp ( for the detection of BSHang construct ). PCR was performed for 35 amplification cycles at 948C for 20 seconds (denaturation ), 588C for 30 seconds ( annealing ) and 728C for 20 seconds (polymerization ). The percentage of integration of inoculated DNA into different tissues was determined from the number of PCR positive samples with respect to the total number of samples examined.
Melanoma cell lines and in vivo treatments
Two human melanoma cell lines, Me501 and 1402P, were selected for melanotic phenotype and for growth capacity in nude mice and maintained in RPMI with 10% FCS. CD1 nu/ nu 6-week -old male mice ( purchased from Charles River, Calco, Italy ) were injected intradermally ( i.d. ) in the left and right flanks with melanoma cells, at doses ranging between 1Â10 6 and 3Â10 6 in the different experiments (see legend to Fig 1 ) . After 1 week, mice were randomized into groups of five to seven and treated weekly by intratumoral (i.t. ) or intraperitoneal (i.p. ) injection. Treatment was continued for 5 ±6 weeks until bigger tumor nodules begun to ulcerate. Control mice were given liposomes with PGKlacZ vector or were left untreated: no difference was seen in our model between PGKlacZ /liposome -treated and untreated mice ( data not shown ), as this treatment, as well as treatment with liposomes only, was shown not to affect tumor growth ( data not shown). When a palpable tumor mass was not evident, intratumoral injections were performed in the skin region showing a dark spot resulting after the injection of melanoma cells. Tumor diameters were measured with a caliper before each treatment and 1 week after the last one. Tumor volume was calculated using the formula width 2 ÂlengthÂ0.5, where the length was taken between the two most distant points of the tumor mass, and the width was measured right -angled to the length. Tumor volumes were plotted versus days after inoculation; statistical significance was evaluated by Student's t test and MannWhitney test.
Vessel density and apoptotic index evaluation
Tumor vascularization was evaluated on cryostatic sections by immunohistochemical staining. A rat anti -mouse CD -31 monoclonal antibody (Mec13.3 ), a specific marker of endothelial cells, 17 was applied as primary antibody and its specific binding was revealed by the avidin ±biotin ± peroxidase complex ( ABC ) procedure 18 as described in a previous report.
14 Vector NovaRED ( Vector Laboratories, Burlingame, CA ) was employed as a chromogen. Vessel density was evaluated by microscopic examination in the area of tumor selected for the highest vascularization. Vessels were counted on three 0.15 -mm 2 fields at 400Âmagnification, and the mean was calculated. 19, 20 For determination of apoptotic index, 5-m -thick sections were cut from formalin -fixed, paraffin -embedded tumor blocks, mounted on poly -Llysine-coated slides, and stained with the TdT-mediated dUTP nick -end labeling ( TUNEL ) reaction, 21 using the in situ cell death detection POD kit (Boehringer Mannheim, Ingelheim, Germany ). Vector NovaRED (Vector Laboratories ) was used as chromogen and hematoxylin as counterstain. For each case, TUNEL positive apoptotic cells were counted in 10 randomly chosen microscopic fields delimited by a microscopic grid of 0.081 mm 2 
RESULTS
To evaluate the antitumor effect of angiostatin gene therapy, CMVang vector carrying murine angiostatin gene under the control of CMV promoter was admixed with liposomes and injected locally, i.d. in the flank, in mice bearing grafted melanoma cells. Intratumor angiostatin gene delivery significantly reduced melanoma growth when compared to controls, an effect observed in mice bearing either Me501 or 1402P melanoma, the latter showing a faster growth rate ( Fig 1, A and B ) . Treatment with MMTVang plasmid vector, which was tested in previous studies, 14 showed similar growth inhibitory activity in mice bearing Me501 melanoma, whereas CMVang was more effective than MMTVang in mice bearing 1402P melanoma ( data not shown ). Me501 tumors evaluated at the end of treatment measured 19 7 and 15 4 mm 3 in mice treated with CMVang and with MMTVang, respectively, and 190 64 mm 3 in controls, with a reduction of tumor mass of 89% and 92% (P < .01 ). In contrast, 1402P melanomas were reduced by 77% and 38%, respectively, by the two treatments (145 104 mm 3 in mice treated with CMVang, 380 239 mm 3 with MMTVang, and 631 195 mm 3 in controls, P < .05 for CMVang vs. control ). To assess whether local treatment with angiostatin gene exerted also a systemic effect, mice transplanted with Me501 melanoma cells in both flanks were injected with the CMVang vector in the tumor of one flank only and the growth was monitored for both tumor masses. The growth of untreated controlateral tumors was significantly sup- Figure 1C ( 63 6 vs. 284 134 mm 3 of controls, P < .01 ). The growth curves of the treated and the untreated tumors in monolaterally injected mice bearing two melanomas were shown to be similar ( not shown).
The antitumor effect of systemically delivered angiostatin gene was further evaluated in mice treated systemically by i.p. injections. In mice injected with Me501 cells, treatment with CMVang determined 90% growth reduction ( mean 21.7 16.1, vs. 237.6 72.7 of control mice, P < .01), further indicating that angiostatin gene therapy inhibits melanoma growth by a systemic effect (Fig 1D ) .
Both tumor growth suppression and delayed growth rate were observed in treated mice. Altogether, Me501 growth was suppressed in 14 of 18 mice treated locally and in 18 of 25 animals after systemic treatment with CMVang, whereas tumor growth was not affected or unrestrained in 17 control mice treated i.p. with PGKlacZ vector or in 24/ 28 untreated controls (P < .01, as determined using Mann -Whitney test to compare treated mice with untreated controls ).
Finally, BSHang vector carrying human angiostatin gene was tested for antitumoral activity by local and systemic delivery. Experiments showed reduced tumor growth rate in treated mice when compared to treatment with liposomecoated plasmid PGKlacZ (Fig 1, panels E and F ) . Mean tumor mass was reduced by 80% and 50%, respectively, after the course of i.t. and i.p. treatments (mean tumor masses were 60 25 after local treatment, 141 41 after i.p. treatment, 285 79 in controls, and 211 69 mm 3 after i.p. treatment with PGKlacZ plasmid, P < .05).
PCR performed on tumors and tissues from treated mice showed that at the time of sacrifice the lipofected angiostatin vector DNA was present at different degrees in tissues from treated but not from control mice ( Table 1 ). The expression of injected angiostatin gene was also detected by RT-PCR in tumors after local treatment, whereas no expression was detected in the controlateral untreated tumors in mice bearing two melanomas (data not shown).
Vessel density was evaluated in tumors from mice treated systemically with BSHang vector and in tumors from untreated controls. A lower vessel density was shown in treated mice in comparison with untreated controls (Table  2 ) , although the differences were not statistically significant. TUNEL staining was also performed to evaluate tumor cells undergoing apoptosis. Higher apoptotic index values were scored in tumors from mice treated with BSHang i.p. compared to untreated controls ( P <.05 ).
DISCUSSION
Angiogenic factors induced after the local decrease in oxygen concentration and nutrient supply due to inadequate vasculature are known to initiate tumor neovascularization. 22 Although the regulators of angiogenesis that are biologically relevant for melanoma are yet undefined, several angiogenic factors, which are induced in hypoxic conditions, such as bFGF, VEGF, IL -8, or angiogenin, show enhanced expression in melanoma metastases in vivo and in highly metastatic cell lines. 23 ± 26 However, because multiple factors are involved in the angiogenesis of melanoma 27, 28 it is unlikely that the specific targeting of single angiogenic factor pathways would result in the complete inhibition of tumor angiogenesis.
The present report demonstrates that gene therapy with murine and human angiostatin gene by liposome delivery inhibits local and distant human melanoma growth in nude mice, after intratumor or intraperitoneal administration. This finding strengthens the potential clinical usefulness of angiostatic gene treatment for metastatic melanoma, a disease that in its advanced phase is refractory to conventional treatments. 29 In the present study, we tested against human melanoma growing in nude mice the liposome-based angiostatin gene approach used in our previous studies. 14, 16 Gene delivery represents an efficient method to achieve intratumoral constant concentrations of angiostatin, which are necessary, due to its short in vivo half life, to obtain clinical benefits, although the amount of protein delivered by this approach cannot be exactly quantified. 30 DNA ± liposome complexes represent a feasible treatment modality because they are easily prepared, have already been used in clinical trials as well as in cosmetics, show little if any toxicity after local or parenteral administration, can be repeatedly administrated, do not raise immunological responses, and are devoid of any danger of recombination with endogenous viral sequences. 31 Our data show that angiostatin gene therapy caused melanoma growth inhibition by systemic effects. In fact, in mice bearing two melanomas of which only one was treated, both tumors were significantly inhibited by angiostatin gene delivery, and tumor growth inhibition was observed also after systemic i.p. delivery. Both CMVang and BSHang vectors carrying the murine and the human angiostatin gene, respectively were shown to inhibit Me501 growth. The absence of species specificity has been reported also in other studies showing the efficacy of human angiostatin in murine tumor models. 16, 32 The efficacy of angiostatin gene delivery against melanoma shown here is in agreement with data obtained in mice bearing syngeneic B16 murine melanoma. 15, 32 The mechanisms leading to the antitumor properties of angiostatin are still undefined. Recently, it has been shown that angiostatin -mediated regulation of plasmin formation results in the inhibition of in vitro invasiveness of endothelial and melanoma cell, thus suggesting an effect on tumor cell migration. 33 In the present study, a low vascular density was shown in the Me501 xenografts, and tumors were mostly necrotic at the time of examination. Vascular densities ranging between 10 to 40 vessels /mm 2 were shown in human melanoma xenografts obtained from different cell lines, a difference that was not correlated with metastatic potential in nude mice. 34 Nonetheless, in our study, tumors from mice given angiostatin gene therapy displayed a lower vessel density, thus indicating that treatment limited tumor vasculature, a data indirectly confirmed by the increase in apoptotic index values observed in these tumors.
In this study, both melanoma growth suppression and delayed tumor growth has been observed in treated mice in which angiostatin gene was delivered before the appearance of clinically detectable tumour nodules. Taken together, therefore, these results suggest that angiostatin gene administration could affect melanoma metastatic dissemination and be useful as an adjuvant treatment after surgery as well as a local treatment in patients with in transit metastases of melanoma.
